Since elevated IGF-1 levels are positively associated with cancer risk, although this relationship is far from definitive, one might expect that if soy increases levels of this hormone, it would also increase risk of cancer. Epidemiologic studies suggest just the opposite that higher soy intake is associated with a decreased risk of breast [74] and prostate [75,76,77] cancer. However, mean soy protein intake, which comes from traditional Asian soyfoods in the vast majority of these epidemiologic studies, is below the amounts associated with increases in IGF-1 in the clinical studies so the insight this research provides is limited. In addition, most of the clinical studies that evaluated markers of breast or prostate cancer risk intervened with isoflavone supplements, so this research provides limited insight regarding the effects of soy protein on IGF-1 levels, but it is worth emphasizing that almost without exception, these studies show that soy does not adversely affect breast [78,79,80] or prostate [81, 82] tissue. As is the case with bone health, most interest in the cancer and soy relationship is because of isoflavones.
In conclusion, the evidence that large amounts (40 g/day) of soy protein increase unbound IGF-1 in comparison with dairy protein is unimpressive. However, it is possible that as a high-quality protein, soy protein may increase IGF-1 levels among those who do not consume animal protein, but the evidence in support of this speculation is extremely limited. Furthermore, all of the starting and ending IGF-1 values for both the control and soy protein groups fell within the normal reference range [83]. Given all of the evidence, a reasonable conclusion is that a decision to incorporate soyfoods into the diet should not be based on the possible effects on IGF-1 system.